Author: Laubscher, G. J.; Lourens, P. J.; Venter, C.; Grobbelaar, L. M.; Kell, D. B.; Pretorius, E.
Title: A decision-tree approach to treat platelet hyperactivity and anomalous blood clotting in acute COVID-19 patients Cord-id: e88bk5em Document date: 2021_7_7
ID: e88bk5em
Snippet: The coronavirus disease 2019 (COVID-19) (SARS-Cov-2) has caused a worldwide, sudden and substantial increase in hospitalizations for pneumonia with multiorgan problems. An important issue is also that there is still no unified standard for the diagnosis and treatment of COVID-19. Substantial vascular events are significant accompaniments to lung complications in COVID-19 patients. Various papers have now also shown the significance of thromboelastrography (TEG) as point-of-care technology to det
Document: The coronavirus disease 2019 (COVID-19) (SARS-Cov-2) has caused a worldwide, sudden and substantial increase in hospitalizations for pneumonia with multiorgan problems. An important issue is also that there is still no unified standard for the diagnosis and treatment of COVID-19. Substantial vascular events are significant accompaniments to lung complications in COVID-19 patients. Various papers have now also shown the significance of thromboelastrography (TEG) as point-of-care technology to determine the levels of coagulopathy (both clotting and bleeding) in COVID-19, in managing COVID-19 patients. Here we present two treatment protocols that may used to treat thrombotic and bleeding or thrombocytopenia pathologies. We also present a case study, where the thrombotic pathology was successfully treated with the thrombotic protocol. Both the protocols use clinical parameters like D-dimer and CRP, as well as the TEG, to closely follow the daily clotting propensity of COVID-19 patients. We conclude by suggesting that the treatment of COVID-19 patients, should be based on a combination of blood biomarkers, and results from point-of-care analyses like the TEG. Such a combination approach closely follow the physiological responses of the immune system, the haematological, as well as the coagulation system, in real-time.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and lmwh unfractionated heparin: 1
- acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and lung autopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute hypoxic respiratory failure and lopinavir ritonavir: 1
- acute hypoxic respiratory failure and lopinavir ritonavir treatment: 1
- acute hypoxic respiratory failure and low mortality: 1
- acute patient and adjuvant treatment: 1, 2, 3
- acute patient and lmwh weight heparin: 1, 2
- acute patient and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
- acute patient and lopinavir ritonavir treatment: 1, 2
- acute patient and low molecular lmwh weight heparin: 1, 2
- acute patient and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute patient and low mortality: 1, 2, 3
- acute patient and low risk patient: 1, 2
Co phrase search for related documents, hyperlinks ordered by date